2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.06 Real-World Cases on Efficacy and Safety of Savolitinib for Elderly Patients with NSCLC Harbouring METex14 Skipping Mutations

EP.12D.06 Real-World Cases on Efficacy and Safety of Savolitinib for Elderly Patients with NSCLC Harbouring METex14 Skipping Mutations

Back to course

Pdf Summary

The document outlines a study on the efficacy and safety of savolitinib, a MET tyrosine kinase inhibitor, in treating elderly patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. It focuses on real-world cases, specifically three elderly NSCLC patients aged 76, 83, and 86, who were treated with savolitinib as part of a retrospective review conducted between 2022 and 2024.<br /><br />**Study Introduction and Objective:**<br /><br />The MET gene plays a significant role in tumor formation and metastasis. Savolitinib is the first small molecule inhibitor in China approved for treating NSCLC with METex14 mutations. The study aims to report outcomes in three elderly NSCLC patients using savolitinib, exploring its efficacy and safety.<br /><br />**Patients and Baseline Characteristics:**<br /><br />- **Case 1:** An 83-year-old male diagnosed with stage IV lung adenocarcinoma.<br />- **Case 2:** An 86-year-old female diagnosed with stage IVa NSCLC with extensive lymph node metastases.<br />- **Case 3:** A 76-year-old male diagnosed with stage IV adenocarcinoma.<br /><br />All patients confirmed METex14 skipping mutations via Next Generation Sequencing (NGS).<br /><br />**Treatment and Results:**<br /><br />- **Case 1** received a 600 mg daily dose of savolitinib, achieving partial response and stable disease over 15 months, with mild fatigue and pruritus as side effects.<br />  <br />- **Case 2** began with 600 mg Qd but required dosage reductions due to hepatic dysfunction. With radiotherapy added, the progression-free survival (PFS) exceeded 25 months. Side effects included limb edema and rash.<br />  <br />- **Case 3** commenced at 400 mg Qd, also experiencing hepatic dysfunction prompting dosage reduction. Additional side effects included grade 2 hypoproteinemia.<br /><br />**Conclusion and Future Directions:**<br /><br />Savolitinib demonstrated clinical benefits and an acceptable safety profile in elderly patients with METex14 skipping mutations, suggesting its potential as an effective treatment option. The study emphasizes the need for further real-world data collection to better understand long-term efficacy and safety outcomes.

Asset Subtitle

Lailing Li

Meta Tag

Speaker Lailing Li

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

savolitinib

MET tyrosine kinase inhibitor

non-small cell lung cancer

NSCLC

MET exon 14 skipping mutations

elderly patients

retrospective review

efficacy and safety

real-world cases

Next Generation Sequencing